Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.36 - $7.60
Previous CloseN/A
Volume8.30K
Average Volume (3M)3.00K
Market Cap
$147.59M
Enterprise Value$1.32M
Total Cash (Recent Filing)$130.91M
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding40,374,640
10 Day Avg. Volume7,082
30 Day Avg. Volume2,996
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$10.50Price Target Upside180.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMolecular Partners Ag presented its second Radio-DARPin candidate targeting mesothelin for ovarian cancer, showing promising preclinical data.
LeadershipStrengthened leadership via appointment of Martin Steegmaier.
Regulatory ProgressMOLN announced that the previously planned Phase 0 imaging study for MP0712 is no longer necessary following discussions with the FDA, allowing the company to proceed directly into a Phase I dose escalation study.
Bears Say
Antidrug AntibodiesAntidrug antibodies (ADAs) were detected in 66% of patients, which coincided with reduced serum MP0533 exposure levels, posing a challenge to treatment efficacy.
Treatment EfficacyDespite efforts to mitigate ADA development, the presence of ADAs remains a significant concern that could affect treatment outcomes.
Workforce ReductionMOLN announced that the company intends to reduce its current workforce by no more than 40 positions, representing up to ~24% of all headcounts.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.36 and its highest was $7.60 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $147.59M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 18, 2026 which is in 200 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2025. The company reported -$0.58 earnings per share for the quarter, the consensus estimate of -$0.58 by $0.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.58 in its last earnings report, expectations of -$0.58. Following the earnings report the stock price went down -7.82%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
Molecular Partners Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (180.00% Upside)
$10.50 (180.00% Upside)
Blogger Sentiment
Bullish
MOLN Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.80%
12-Months-Change
Fundamentals
Return on Equity
-48.90%
Trailing 12-Months
Asset Growth
-17.79%
Trailing 12-Months
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$10.50
▲(180.00% Upside)
Technical Analysis
Sangamo Biosciences
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―
Third Harmonic Bio, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---